Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tranzyme Pharma has initiated dosing in a Phase I study of TZP-102, the company's second generation, orally-administered ghrelin agonist, for the treatment of mild-to-moderate gastroparesis, with other chronic gastrointestinal motility disorders to follow.
Subscribe to our email newsletter
The trial is a two-part double-blind, placebo-controlled evaluation of single ascending doses, followed by a crossover multi-dose evaluation in healthy human volunteers. In addition to safety, other objectives of the study include the assessment of pharmacokinetic properties and pharmacodynamic effects of ghrelin receptor agonist activity.
Gordana Kosutic, vice president, regulatory and clinical affairs at Tranzyme, said: “We are very excited to begin characterizing the safety and tolerability of TZP-102. We anticipate progressing TZP-102 into Phase II investigation by the end of this year.”